Georges Pompidou Hospital Reports Clear Labelling of Malignant Cells

PROTOKINETIX INC.            (PKTX : OTCBB)
Vancouver, British Columbia, May 20, 2004

ProtoKinetix Inc. announces today that it has received a report from the Georges Pompidou Hospital in Paris on the first 40 patients studied with RECAF™ on mammary tissue.  The report states that “there is a constant expression of RECAF on tumoral epithelial cells, mainly strong expression.”

Based on these results, the Georges Pompidou Hospital will be proceeding to test the RECAF antibody on additional cancers.  The Scientific Advisory Board of ProtoKinetix is satisfied that these third-party validation results have confirmed the presence of the RECAF receptor site on cancer cells.  ProtoKinetix will commence immediately with the design of a research program towards the development of a therapeutic agent.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements.  Some information included in this press release contains statements that are forward-looking.  Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company.  For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

On behalf of the Board of Directors,
Dr. John Todd, President

Company Office:           
1500-885 West Georgia Street           
Vancouver, BC  V6C 3E8                  

Investor Contact:
BCGU, Business Consulting Group Unlimited
www.bcgu.com
In the U.S. (888) 772-1288
Outside the U.S.: +011 (858) 523-0122